Ulcerative colitis: Correlation of the Rachmilewitz Endoscopic Activity Index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes

Inflammatory Bowel Diseases

Volumn 15, Issue 12, 2009, Pages 1851-1858

  Schoepfer, Alain M ^a,b   Beglinger, Christoph ^c   Straumann, Alex ^c   Trummler, Michael ^d   Renzulli, Pietro ^a   Seibold, Frank ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d Bioanalytica Medical Laboratories   (Switzerland)

Author keywords

Biomarkers; Disease activity; Fecal calprotectin; Rachmilewitz Activity Index; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALGRANULIN; CORTICOSTEROID; MERCAPTOPURINE; MESALAZINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; AGED; ARTICLE; COLONOSCOPY; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; ENDOSCOPY; FECES ANALYSIS; FEMALE; HUMAN; LEUKOCYTE COUNT; LEUKOCYTOSIS; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RELIABILITY; ULCERATIVE COLITIS;

ADULT; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; COLITIS, ULCERATIVE; COLONOSCOPY; FECES; FEMALE; HUMANS; LEUKOCYTE COUNT; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 72549104759     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20986     Document Type: Article

References (38)

1. Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut. 2006;55:426-431.
2. Mazlam MZ, Hodgson JH. Peripheral blood monocyte cytokine production and acute phase response in inflammatory bowel disease. Gut. 1992;33:773-778.
3. Bitton A, Peppercorn M, Antonioli D, et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology. 2001;120:13-20. (Pubitemid 32061864)
4. Linskens R, van Bodegraven A, Schoorl M, et al. Predictive value of inflammatory and coagulation parameters in the course of severe ulcerative colitis. Dig Dis Sci. 2001;46:644-648. (Pubitemid 32299823)
5. Johne B, Fagerhol MK, Lyberg T, et al. Functional and clinical aspects of the myelomonocytic protein calprotectin. J Clin Pathol Mol Pathol. 1997;50:113-123. (Pubitemid 27454995)
6. Schoepfer AM, Trummler M, Seeholzer P, et al. Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies. Inflamm Bowel Dis. 2008;14:32-39. (Pubitemid 351196866)
7. Tibble JA, Sightorsson G, Bridger S, et al. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology. 2000;119:15-22. (Pubitemid 30452574)
8. Costa F, Mumolo MG, Ceccarelli L, et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut. 2005;54:364-368. (Pubitemid 40299092)
9. Roseth AG, Aadland E, Jahnsen J, et al. Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. Digestion. 1997;58:176-180. (Pubitemid 27163169)
10. Roseth AG, Aadland E, Grzyb K. Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease. Scand J Gastroenterol. 2004;39:1017-1020. (Pubitemid 39388470)
11. Canani RB, Terrin G, Rapacciuolo L, et al. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease. Dig Liver Dis. 2008;40:547-553.
12. Langhorst J, Elsenbruch S, Koelzer J, et al. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol. 2008;103:162-169.
13. Silberer H, Küppers S, Mickisch, et al. Fecal leukocyte proteins in inflammatory bowel disease and irritable bowel syndrome. Clin Lab. 2005;51:117-126. (Pubitemid 40520584)
14. Langhorst J, Elsenbruch S, Mueller T, et al. Comparison of 4 neutrophil-derived proteins in feces as indicators of disease activity in ulcerative colitis. Inflamm Bowel Dis. 2005;11:1085-1091. (Pubitemid 41682565)
15. Arnott ID, Watts D, Ghosh S. Review article: is clinical remission the optimum therapeutic goal in the treatment of Crohn's disease? Aliment Pharmacol Ther. 2002;16:857-867.
16. Froslie KF, Jahnsen J, Moum BA, et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology. 2007;133:412-422. (Pubitemid 47187355)
17. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. Br Med J. 1989;298:82-86. (Pubitemid 19032930)
18. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317:1625-1629.
19. Nikolaus S, Schreiber S. Review article: diagnostics of inflammatory bowel disease. Gastroenterology. 2007;133:1670-1689.
20. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19(suppl A):5-36.
21. Walkiewicz D, Werlin SL, Fish D, et al. Fecal calprotectin is useful in predicting disease relapse in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2008;14:669-673. (Pubitemid 351742984)
22. D'Incà R, Dal Pont E, Di Leo V, et al. Can calprotectin predict relapse risk in inflammatory bowel disease? Am J Gastroenterol. 2008;103:2007-2014.
23. Wagner M, Peterson CGB, Ridefelt P, et al. Fecal markers of inflammation used as surrogate markers for treatment outcome in relapsing inflammatory bowel disease. World J Gastroenterol. 2008;14:5584-5589.
24. Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol. 2005;100:1345-1353.
25. Van Staa TP, Card T, Logan RF, et al. 5-aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut. 2005;54:1573-1578. (Pubitemid 41531774)
26. Tibble JA, Sightorsson G, Bridger S, et al. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology. 2000;119:15-22. (Pubitemid 30452574)
27. Roseth AG, Aadland E, Jahnsen J, et al. Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. Digestion. 1997;58:176-180. (Pubitemid 27163169)
28. Schoepfer AM, Trummler M, Seeholzer P, et al. Accuracy of four fecal assays in the diagnosis of colitis. Dis Colon Rectum. 2007;50:1697-1706. (Pubitemid 47583348)
29. Summerton CB, Longlands MG, Wiener K, et al. Faecal calprotectin: a marker of inflammation throughout the intestinal tract. Eur J Gastroenterol Hepatol. 2002;14:841-845. (Pubitemid 34913581)
30. Tibble JA, Sigthorsson G, Foster R, et al. High prevalence of NSAID enteropathy as shown by a simple faecal test. Gut. 1999;45:362-366. (Pubitemid 29400711)
31. Roseth AG, Kristinsson J, Fagerhol MK, et al. Faecal calprotectin: a novel test for the diagnosis of colorectal cancer? Scand J Gastroenterol. 1993;28:1073-1076.
32. Daperno M, Sostegni R, Pera A, et al. The role of endoscopic assessment in ulcerative colitis in the era of infliximab. Dig Liver Dis. 2008;40S2:S220-224.
33. Condon A, Graff L, Elliot L, et al. Acceptance of colonoscopy requires more than test tolerance. Can J Gastroenterol. 2008;22:41-47.
34. Simren M, Axelsson J, Gillberg R, et al. Quality of life in inflammatory bowel disease in remission: the impact of IBS-like symptoms and associated psychological factors. Am J Gastroenterol. 2002;97:389-396. (Pubitemid 34160766)
35. Saverymuttu SH, Hodgson HJ, Chadwick VS, et al. Differing acute phase responses in Crohn's disease and ulcerative colitis. Gut. 1986;27:809-813. (Pubitemid 16058500)
36. Carlson CS, Aldred SF, Lee PK, et al. Polymorphisms within the Creactive protein (CRP) promoter region are associated with plasma CRP levels. Am J Hum Genet. 2005;77:64-77.
37. Kane S, Lu F, Kornbluth A, et al. Controversies in mucosal healing in ulcerative colitis. Inflamm Bowel Dis. 2009;15:796-800.
38. Kandiel A, Lashner B. Cytomegalovirus colitis complicating inflammatory bowel disease. Am J Gastroenterol. 2006;101:2857-2865. (Pubitemid 44902661)